![](https://investorshub.advfn.com/uicon/540293.png?cb=1493889813)
Monday, May 29, 2017 12:42:38 PM
Class I - These devices present minimal potential for harm to the user and are often simpler in design than Class II or Class III devices. Examples include enema kits and elastic bandages. 47% of medical devices fail under this category and 95% of these are exempt from the regulatory process.
If a device falls into a generic category of exempted Class I devices, the premarket notification application and FDA clearance is not required before marketing the device in the U.S.
https://www.fda.gov/MedicalDevices/ResourcesforYou/Consumers/ucm142523.htm
If this is so, we may be waiting for an FDA approval that never comes because is not what is being requested now. In the interview they talk that they already have the Class II approval and are not requesting a new one, but instead a Class I "clearance" which is not required according to the FDA rules.
The clinical trial has no influence on the Class I application, but would only serve to confirm that the digital version have slightly lower error rates. That is, it has beneficial effects for its commercialization but no effects at all for the FDA Class I process. The sales in the US can be started at any time when they have completed the administrative procedures of the Class I. No approval is required according to the FDA info. We may not hear anything this year or ever about an FDA approval.
The question is whether the FDA has already classified them as a Class I. If the iTbra doesn't fall into this category we may be facing a new delay, because a new 510(k) will be required, which will also need a completed clinical trial with all the required participants.
My concern is whether the change in strategy has not been due to a clinical trial that has proved valid but has not had the minimum number of participants required for a Class II 510 (k) application.
Can someone clarify this with objective information.
This detail can change many things.
Disclaimer: This information is only my opinion and should not be considered as an advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM